Cite
Utility of Cytochrome P450 4F2 Genotyping to Assess Drug Interaction Risk for Brincidovovir, a Cytochrome P450 4F2 Substrate.
MLA
Tippin, Tim, et al. “Utility of Cytochrome P450 4F2 Genotyping to Assess Drug Interaction Risk for Brincidovovir, a Cytochrome P450 4F2 Substrate.” Clinical Pharmacology in Drug Development, vol. 13, no. 3, Mar. 2024, pp. 288–96. EBSCOhost, https://doi.org/10.1002/cpdd.1356.
APA
Tippin, T., Faison, S., Schuck, V., Dunn, J., & Naderer, O. (2024). Utility of Cytochrome P450 4F2 Genotyping to Assess Drug Interaction Risk for Brincidovovir, a Cytochrome P450 4F2 Substrate. Clinical Pharmacology in Drug Development, 13(3), 288–296. https://doi.org/10.1002/cpdd.1356
Chicago
Tippin, Tim, Shamia Faison, Virna Schuck, John Dunn, and Odin Naderer. 2024. “Utility of Cytochrome P450 4F2 Genotyping to Assess Drug Interaction Risk for Brincidovovir, a Cytochrome P450 4F2 Substrate.” Clinical Pharmacology in Drug Development 13 (3): 288–96. doi:10.1002/cpdd.1356.